Bortezomib: all 701 studies that test it

Page 4 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT05804032Phase 3
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingNCT05392946Phase 1/2
• Bortezomib for Treating Glomerular DiseasesStatus unknownNCT05383547Not applicable
• Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic DisordersWithdrawnNCT05293509Phase 2
• A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentStatus unknownNCT05147493Phase 2
• Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRDStatus unknownNCT05137860Phase 4
• Isa-RVD Study in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05123131Phase 2
• A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Phase 3
• Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Phase 1
• Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedNCT04956302Phase 1
• Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY DiseaseTerminatedNCT04912427Phase 1
• Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe HemoglobinopathiesWithdrawnNCT04776850Early Phase 1
• DARA RVD For High Risk SMMActive, not recruitingNCT04775550Phase 2
• Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).Active, not recruitingNCT04751877Phase 3
• Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM PatientsActive, not recruitingNCT04717700Phase 2
• Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMMActive, not recruitingNCT04653246Phase 2
• Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04570631Phase 1
• Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain AmyloidosisStatus unknownNCT04474938Phase 2
• VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
• Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma PatientsWithdrawnNCT04348006Phase 4
• Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT04285268Phase 2
• Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT04277845Phase 2
• CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in ChildrenCompletedNCT04224571Phase 2
• TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With BortezomibCompletedNCT04173585Phase 2
• Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary DiseaseActive, not recruitingNCT04166565Phase 2
• A Study of Bortezomib Combined With CHEP in Peripheral T Cell LymphomaStatus unknownNCT04061772Phase 2
• Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
• BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)Status unknownNCT03982771Phase 2
• Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03942224Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03829020Phase 1
• Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03763162Phase 2
• Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMRCompletedNCT03737136Not applicable
• Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)Active, not recruitingNCT03729804Phase 3
• Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia AStatus unknownNCT03700229Phase 2
• Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple MyelomaActive, not recruitingNCT03695744Phase 2
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03651128Phase 3
• Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive, not recruitingNCT03620903Phase 2
• Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)Active, not recruitingNCT03617731Phase 3
• Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaWithdrawnNCT03617484Phase 2
• A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesStatus unknownNCT03607643Phase 1/2
• Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaWithdrawnNCT03591744Phase 1
• SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaActive, not recruitingNCT03589222Phase 2
• Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer PatientsStatus unknownNCT03509246Phase 2
• Rituximab Combining Bortezomib Versus Rituximab in Management of ITPStatus unknownNCT03443570Phase 3
• Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for TransplantationCompletedNCT03402295Phase 3
• Bortezomib in Intrahepatic Cholangiocellular CarcinomaStatus unknownNCT03345303Phase 3
• Study of VTD in Waldenstrom's MacroglobulinemiaStatus unknownNCT03335098Phase 2
• A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantActive, not recruitingNCT03319667Phase 3
• A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03314181Phase 2
• MUK Nine b: OPTIMUM Treatment ProtocolActive, not recruitingNCT03188172Phase 2
• 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple MyelomaWithdrawnNCT03168100Phase 2
• Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisWithdrawnNCT03130348Phase 2
• Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
• Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
• Treatment of Adult-Onset Immunodeficiency With BortezomibStatus unknownNCT03103555Phase 2
• The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell LymphomaStatus unknownNCT03016988Phase 2
• A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)Status unknownNCT03013114Phase 2
• 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance TherapyActive, not recruitingNCT03004287Phase 2
• Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal ImpairmentCompletedNCT02977494Phase 2
• PCD Versus RCD for the Treatment of Patients With Waldenstrom's MacroglobulinemiaStatus unknownNCT02971982Phase 1/2
• Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)Status unknownNCT02955810Phase 1
• Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum DisorderCompletedNCT02893111Phase 2
• The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaCompletedNCT02844322Phase 4
• Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell LymphomaCompletedNCT02840539Phase 2
• Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02811978Phase 3
• Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell LymphomasCompletedNCT02783625Phase 1
• Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple MyelomaTerminatedNCT02773550Phase 4
• A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingNCT02718833Phase 2
• GO-203-2C + Bortezomib For Relapsed Or Refractory MMWithdrawnNCT02658396Phase 1
• Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
• Modified Bortezomib-based Combination Therapy for Multiple MyelomaStatus unknownNCT02559154Phase 4
• A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
• Immune Modulation Therapy for Pompe DiseaseStatus unknownNCT02525172Phase 4
• Quantitating the Impact of PlerixaforStatus unknownNCT02522572Phase 1/2
• Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02514382Phase 1
• Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
• A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02497378Phase 1
• Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in ChildrenTerminatedNCT02484261Phase 1
• Relapse Myeloma; Cyclofosfamide; Bortezomib; MaintenanceCompletedNCT02467010Phase 2
• Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell LymphomaTerminatedNCT02356458Phase 1/2
• Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney TransplantationStatus unknownNCT02351427Phase 3
• Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell TransplantationCompletedNCT02312102Phase 1
• Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma PatientsCompletedNCT02308280Phase 2
• A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple MyelomaCompletedNCT02268890Phase 4
• Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple MyelomaCompletedNCT02237261Phase 2
• Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT02220608Phase 1
• Dose Escalation of Velcade Daily Dose in Patients With Solid TumorsCompletedNCT02220049Phase 1
• Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02219178Phase 2
• Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
• Bortezomib in Rejection of Kidney TransplantsCompletedNCT02201576Phase 2
• Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive MyelomaCompletedNCT02188537Phase 2
• Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaStatus unknownNCT02145715Phase 1/2
• Microdose Study of Melphalan, Bortezomib and DexamethasoneStatus unknownNCT02109861Early Phase 1
• Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)TerminatedNCT02102594Phase 2
• Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.Status unknownNCT02086942Phase 2
• Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple MyelomaWithdrawnNCT02082405Phase 2
• Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Phase 2
• A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1

← Bortezomib overview